Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 MAR 23 ... Research (CDER) has decided that available data are not adequate to support approval of Genasense® (oblimersen sodium) Injection for treatment of patients with relapsed or refractory ...
2009 JUN 22 ... in an ongoing pilot study that incorporates the Company's lead oncology product, Genasense® (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced ...
2009 MAY 11 ... to grant two key patents related to the Company’s intellectual property position on Genasense® (oblimersen sodium) Injection. The Company has proceeded with grant formalities and ...
2009 SEP 21 ... to analyze and release the primary data from AGENDA, our randomized Phase 3 trial of Genasense® in patients with advanced melanoma. We continue to anticipate release of these ...
2009 APR 20 ... that the Company had completed patient enrollment into AGENDA, a Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. Final accrual totaled ...
2009 MAY 11 ... announced that data from clinical trials of the Company's late-stage compounds, Genasense® (oblimersen sodium) Injection and tesetaxel, will be presented at the 2009 American ...
2009 NOV 9 ... (OTCBB: GETA) announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a ...
2009 SEP 7 ... anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA ...
2009 MAY 25 ... milestones in the third quarter, including the following: AGENDA Phase 3 trial of Genasense® in melanoma completes enrollment: Final safety and futility analysis expected May 2009 ...
2009 MAR 2 ... Tesetaxel, a leading Phase 2 oral taxane, prepares for pivotal trial in gastric cancer Genasense® intermittent schedule enters trial in melanoma Decision on FDA appeal for...
2009 AUG 24 ... will have sufficient financing that will enable release of primary data in our Phase 3 Genasense® trial in melanoma. Certainly, past and recent studies of other drugs in melanoma ...
2009 FEB 16 ... NYU Medical Center, who is an investigator on the Company’s Phase 3 AGENDA trial of Genasense® in patients with advanced melanoma.
Keywords: Biotechnology Business, ...
2009 NOV 23 ... anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA ...
2009 JUL 20 ... Chief Executive Officer. "Having completed accrual to our randomized Phase 3 trial of Genasense® in patients with advanced melanoma, we expect these proceeds will enable determination ...
2009 APR 20 ... months from the initial closing date or 90 days after the first regulatory approval of Genasense for marketing by the European Medicines Agency (EMEA) or the Food and Drug ...
2009 JAN 26 ... the presentation of a progress update on the Company’s ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product, in patients with advanced ...
2009 JUN 1 ... the independent Data Monitoring Board (DMB) for AGENDA, a randomized Phase 3 trial of Genasense® in patients with advanced melanoma, has informed the Company that the study has passed ...
2009 NOV 25 ... "Using a coaxial needle setup, we produced G3139 (oblimerson sodium, or Genasense) encapsulated lipoplex nanoparticles, and investigated the effects of production ...
2009 JUL 27 ... measured by a widely available blood test. Genta's recently completed Phase 3 trial of Genasense® in advanced melanoma, known as AGENDA, specified low-normal LDH as an enrollment ...
2008 SEP 29 ... Board (DMB) for AGENDA, a Phase 3 trial of the Company's lead oncology product Genasense(R) (oblimersen sodium) Injection, has completed its review. During its review, the DMB ...
